| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Cilazapril 0.5‐10 mg: n=288(166 males,122 females); mean age=53.9(12.1) years; baseline sitting DBP=100.4 mm Hg;
Placebo: n=97(57 males,40 females); mean age=53.0(11.9) years; baseline sitting DBP=100.3 mm Hg |
| Interventions |
Cilazapril 0.5 mg once daily;
Cilazapril 5 mg once daily;
Cilazapril 10 mg once daily;
Placebo;
taken between 8 AM and 10 AM |
| Outcomes |
Mean change from baseline in trough sitting DBP using mercury sphygmomanometer;
WDAE |
| Notes |
SBP not reported; DBP change and SD of change reported, endpoint BP and SD not reported; BP data from Table 3, p. 315; Jadad score=3; funding source= Hoffmann‐La Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
